

## **Velcade (bortezomib): Starting Dose Adjustments for Patients with Hepatic Impairment**

FDA MedWatch

Patients with moderate or severe hepatic impairment should be treated with reduced starting doses and closely monitored.

[SOURCE](#) [1]

**Source URL (retrieved on 01/29/2015 - 1:32pm):**

[http://www.ecnmag.com/news/2010/01/velcade-bortezomib-starting-dose-adjustments-patients-hepatic-impairment?qt-video\\_of\\_the\\_day=0](http://www.ecnmag.com/news/2010/01/velcade-bortezomib-starting-dose-adjustments-patients-hepatic-impairment?qt-video_of_the_day=0)

**Links:**

[1] <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198424.htm>